Institute of Applied Health Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Joint first authors.
BMJ. 2019 Sep 3;366:l4892. doi: 10.1136/bmj.l4892.
To explore whether thyroid stimulating hormone (TSH) concentration in patients with a diagnosis of hypothyroidism is associated with increased all cause mortality and a higher risk of cardiovascular disease and fractures.
Retrospective cohort study.
The Health Improvement Network (THIN), a database of electronic patient records from UK primary care.
Adult patients with incident hypothyroidism from 1 January 1995 to 31 December 2017.
TSH concentration in patients with hypothyroidism.
Ischaemic heart disease, heart failure, stroke/transient ischaemic attack, atrial fibrillation, any fractures, fragility fractures, and mortality. Longitudinal TSH measurements from diagnosis to outcomes, study end, or loss to follow-up were collected. An extended Cox proportional hazards model with TSH considered as a time varying covariate was fitted for each outcome.
162 369 patients with hypothyroidism and 863 072 TSH measurements were included in the analysis. Compared with the reference TSH category (2-2.5 mIU/L), risk of ischaemic heart disease and heart failure increased at high TSH concentrations (>10 mIU/L) (hazard ratio 1.18 (95% confidence interval 1.02 to 1.38; P=0.03) and 1.42 (1.21 to 1.67; P<0.001), respectively). A protective effect for heart failure was seen at low TSH concentrations (hazard ratio 0.79 (0.64 to 0.99; P=0.04) for TSH <0.1 mIU/L and 0.76 (0.62 to 0.92; P=0.006) for 0.1-0.4 mIU/L). Increased mortality was observed in both the lowest and highest TSH categories (hazard ratio 1.18 (1.08 to 1.28; P<0.001), 1.29 (1.22 to 1.36; P<0.001), and 2.21 (2.07 to 2.36; P<0.001) for TSH <0.1 mIU/L, 4-10 mIU/L, and >10 mIU/L. An increase in the risk of fragility fractures was observed in patients in the highest TSH category (>10 mIU/L) (hazard ratio 1.15 (1.01 to 1.31; P=0.03)).
In patients with a diagnosis of hypothyroidism, no evidence was found to suggest a clinically meaningful difference in the pattern of long term health outcomes (all cause mortality, atrial fibrillation, ischaemic heart disease, heart failure, stroke/transient ischaemic attack, fractures) when TSH concentrations were within recommended normal limits. Evidence was found for adverse health outcomes when TSH concentration is outside this range, particularly above the upper reference value.
探讨甲状腺刺激素(TSH)浓度在甲状腺功能减退症患者中的变化与全因死亡率增加以及心血管疾病和骨折风险升高是否相关。
回顾性队列研究。
英国初级保健机构的电子患者记录数据库 Health Improvement Network(THIN)。
1995 年 1 月 1 日至 2017 年 12 月 31 日期间确诊为甲状腺功能减退症的成年患者。
甲状腺功能减退症患者的 TSH 浓度。
缺血性心脏病、心力衰竭、中风/短暂性脑缺血发作、心房颤动、任何骨折、脆性骨折和死亡率。从诊断到结局、研究结束或随访丢失,收集了纵向 TSH 测量值。对于每个结局,采用包含 TSH 作为时变协变量的扩展 Cox 比例风险模型进行拟合。
共纳入 162369 例甲状腺功能减退症患者和 863072 次 TSH 测量值。与参考 TSH 类别(2-2.5 mIU/L)相比,高 TSH 浓度(>10 mIU/L)时,缺血性心脏病和心力衰竭的风险增加(风险比 1.18(95%置信区间 1.02-1.38;P=0.03)和 1.42(1.21-1.67;P<0.001))。在低 TSH 浓度(TSH <0.1 mIU/L 时风险比为 0.79(0.64-0.99;P=0.04),0.1-0.4 mIU/L 时风险比为 0.76(0.62-0.92;P=0.006))时,心力衰竭的风险呈保护性降低。在最低和最高 TSH 类别中,均观察到死亡率升高(风险比 1.18(1.08-1.28;P<0.001)、1.29(1.22-1.36;P<0.001)和 2.21(2.07-2.36;P<0.001),TSH <0.1 mIU/L、4-10 mIU/L 和>10 mIU/L)。在 TSH 最高类别(>10 mIU/L)患者中,观察到脆性骨折风险增加(风险比 1.15(1.01-1.31;P=0.03))。
在诊断为甲状腺功能减退症的患者中,当 TSH 浓度在推荐的正常范围内时,未发现 TSH 浓度与长期健康结局(全因死亡率、心房颤动、缺血性心脏病、心力衰竭、中风/短暂性脑缺血发作、骨折)模式存在有临床意义的差异。当 TSH 浓度超出该范围时,特别是高于上限参考值时,发现存在不良健康结局的证据。